{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:04:22Z","timestamp":1794956662647,"version":"4.9.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>To assess the economic burden of tenosynovial giant cell tumor (TGCT) among US employed workforce.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients with TGCT medical claims (<jats:italic toggle=\"yes\">N<\/jats:italic>\u200a=\u200a1395) and matched controls (1:10) without TGCT claims (<jats:italic toggle=\"yes\">N<\/jats:italic>\u200a=\u200a13,950) were identified from the OptumHealth Care Solutions, Inc. database (January 1, 1999 to March 31, 2017). Adjusted regression models were used to compare healthcare resource utilization, time lost from work, and associated costs between cohorts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In patients with TGCT, the rates of inpatient admissions, emergency room visits, outpatient visits, and work loss days were 2.8, 1.5, 2.2, and 2.6 times those of matched controls, respectively (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001). Total annual all-cause healthcare costs and work loss-related costs were $9368 and $2708 higher for TGCT patients than for matched controls, respectively (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>TGCT was associated with a significant healthcare and work loss burden on US employers.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/jom.0000000000002159","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T07:13:22Z","timestamp":1612595602000},"page":"e197-e202","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["The Economic Burden of Tenosynovial Giant Cell Tumors Among Employed Workforce in the United States"],"prefix":"10.1097","volume":"63","author":[{"given":"Feng","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Ionescu-Ittu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Pivneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Wynant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Q.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winghan J.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.3899\/jrheum.160816","article-title":"Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. A Registry-based Cohort Study in Denmark","volume":"44","author":"Ehrenstein","year":"2017","journal-title":"J Rheumatol"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumors","volume":"88","author":"Mastboom","year":"2017","journal-title":"Acta Orthop"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/CCO.0b013e328347e1e3","article-title":"Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis","volume":"23","author":"Ravi","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2016.04.022","article-title":"Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future perspectives","volume":"63","author":"Staals","year":"2016","journal-title":"Eur J Cancer"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.otsr.2016.11.002","article-title":"Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)","volume":"103","author":"Gouin","year":"2017","journal-title":"Orthop Traumatol Surg Res"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/1097-0142(19860215)57:4<875::AID-CNCR2820570432>3.0.CO;2-Y","article-title":"Giant cell tumor of the tendon sheath (nodular tenosynovitis). A study of 207 cases to compare the large joint group with the common digit group","volume":"57","author":"Ushijima","year":"1986","journal-title":"Cancer"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12891-019-2453-z","article-title":"Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol","volume":"20","author":"Takeuchi","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00005792-198005000-00004","article-title":"Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166 cases and literature review","volume":"59","author":"Myers","year":"1980","journal-title":"Medicine (Baltimore)"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/01.blo.0000224051.01873.fb","article-title":"What affects the recurrence and clinical outcome of pigmented villonodular synovitis?","volume":"450","author":"Chiari","year":"2006","journal-title":"Clin Orthop Relat Res"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","article-title":"Tenosynovial giant cell tumour\/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors","volume":"51","author":"Palmerini","year":"2015","journal-title":"Eur J Cancer"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1007\/s11999-009-0922-7","article-title":"Outcomes after excision of pigmented villonodular synovitis of the knee","volume":"467","author":"Sharma","year":"2009","journal-title":"Clin Orthop Relat Res"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/rheumatology\/keu230","article-title":"Long-term follow-up results of primary and recurrent pigmented villonodular synovitis","volume":"53","author":"Verspoor","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2196\/ijmr.9325","article-title":"The patient perspective on the impact of tenosynovial giant cell tumors on daily living: crowdsourcing study on physical function and quality of life","volume":"7","author":"Mastboom","year":"2018","journal-title":"Interact J Med Res"},{"issue":"(15_suppl)","key":"R14-20250804","first-page":"e18737","article-title":"Treatment patterns of tenosynovial giant cell tumor among commercially insured patients: a retrospective claims analysis","volume":"36","author":"Feng","year":"2018","journal-title":"J Clin Oncol"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"593.e1","DOI":"10.1016\/j.clinthera.2018.03.001","article-title":"Burden of illness associated with tenosynovial giant cell tumors","volume":"40","author":"Burton","year":"2018","journal-title":"Clin Ther"}],"container-title":["Journal of Occupational &amp; Environmental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JOM.0000000000002159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T19:17:54Z","timestamp":1754335074000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JOM.0000000000002159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/jom.0000000000002159","relation":{},"ISSN":["1076-2752","1536-5948"],"issn-type":[{"value":"1076-2752","type":"print"},{"value":"1536-5948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]}}}